Chiesi Pharmaceuticals is fully committed to improving the quality of life of people suffering from respiratory diseases, including asthma and COPD (Chronic Obstructive Pulmonary Disease).
According to the latest estimates by the World Health Organization (WHO), there are 235 million people worldwide – mainly children – suffering from asthma, while 64 million people suffer from COPD (WHO 2004 estimate), which is predicted to be the third leading cause of mortality by 2030.
If measures to reduce disease-related risk factors such as cigarette smoke are not adopted, it is estimated that COPD-related deaths will increase by 30% over the next 10 years.
In pursuit of the continuous improvement of patient health, Chiesi Pharmaceuticals researches and develops new therapeutic solutions based on the innovative formulation technology Modulite®, which creates pressurized solutions (pMDI, pressurized metered dose) for inhalation, capable of releasing extra-fine particles. Chiesi Pharmaceuticals has patented and brought to market a medical device holding powder to innalation (DPI, dry powder inhaler), that is also capable of providing extrafine particles.
For more information on asthma, chronic bronchitis / COPD and rhinitis, click here.
